AOTI (AOTI) H2 2024 earnings summary

Executive summary

• Achieved strong revenue growth of 32.9% to $58.4 million, driven by Medicaid and VA expansion, commercial execution, and new product launches.

• Maintained high gross margins in the high 80s, with a shift in revenue mix toward higher-margin Medicaid and commercial sectors.

• Expanded market access to nine Medicaid states, secured a five-year VA contract extension, and launched NEXA with FDA clearance and new distribution agreements.

• Invested in value-based care initiatives, digital platforms, and strengthened management with a new CFO and expanded sales teams.

Financial highlights

• Revenue increased to $58.4 million from $43.9 million, with Medicaid revenue up 84% to $21.5 million and VA revenue up 9% to $34.4 million.

• Gross profit margin improved to 88% from 85.6% year-over-year.

• Adjusted EBITDA grew 368.7% to $8.1 million, with margin rising from 3.9% to 13.8%.

• Net loss narrowed to $1.8 million from $8.2 million; underlying profit (excluding one-offs) reached $4.3 million.

• Cash and cash equivalents rose to $9.3 million, reflecting IPO proceeds and improved net cash position.

Outlook and guidance

• Projected revenue growth of 27–30% for 2025, with Adjusted EBITDA margin expected between 14–16%, weighted to the second half.

• Plans to open 2–3 new Medicaid states annually, deepen commercial sector penetration, and expand international sales.

• Continued investment in value-based care, digital engagement platforms, and sales infrastructure to drive future growth.